🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Rectal Adenocarcinoma

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer NCT05672524Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Trastuzumab, Tucatinib A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Short-course Radiotherapy, SCRT, Toripalimab ADAR1 Expression Level in Rectal Cancer NCT07108348n/a1 site📍 Konya Necmettin Erbakan University · Tests: Adenosine deaminase acting on RNA1 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165Phase 21 site📍 Shanghai Ruijin Hospital · Tests: PD-1 inhibitor based immunotherapy Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC NCT06791512Phase 31 site📍 Guangzhou Jun Huang · Tests: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer NCT04703101Phase 11 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer NCT06205836Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Cemiplimab, Fianlimab Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement NCT07104604Phase 22 sites📍 Shantou📍 Shantou Affiliated Cancer Hospital of Shantou University Medical Co… · Tests: Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer NCT07458529Phase 21 site📍 Beijing Seventh Medical Center of PLA General Hospital · Tests: CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates NCT07292298Phase 23 sites📍 Aurora📍 Rochester📍 Portland University of Colorado, Denver · Tests: High Rare Dose Rectal Brachytherapy Boost A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer NCT07200141Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: GTV 58.75 Gy/25 fractions(Simultaneous Integrated Boost), GTV 50 Gy/25 fractions(Simultaneous Integrated Boost), Concur… A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression NCT06051695Phase 1, Phase 212 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B694, A2B543, xT CDx with HLA-LOH Assay A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497Phase 3244 sites📍 Phoenix📍 Fountain Valley📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium, 5-Fluorouracil, Cetuximab Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer NCT06276686EARLY Phase 11 site📍 Cottingham University of Hull · Tests: Supervised Vigorous intensity aerobic interval exercise ABCSG R07 Rectal Cancer Registry NCT07780305n/a6 sites📍 Wiener Neustadt📍 Salzburg📍 Graz Austrian Breast & Colorectal Cancer Study Group A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) NCT06028724n/a1 site📍 Aviano Centro di Riferimento Oncologico - Aviano Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726Phase 21 site📍 Hangzhou Zhejiang University · Tests: Serplulimab, Capecitabine, Oxaliplatin, Celecoxib Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision NCT05772923NA7 sites📍 Nijmegen📍 Eindhoven📍 Amsterdam The Netherlands Cancer Institute · Tests: Contact x-ray brachytherapy, Local excision PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients NCT06762405Phase 31 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient) First in Human Study of SIM0610 in Solid Tumors NCT07348211Phase 17 sites📍 Chongqing📍 Harbin📍 Shenyang Jiangsu Simcere Pharmaceutical Co., Ltd. · Tests: SIM0610 for Injection, SIM0610 for Injection Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868Phase 320 sites📍 Arnhem📍 Arnhem📍 Nijmegen J. W. A. Burger · Tests: FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Chemoradiotherapy, Total mesorectal excision (+/- I… A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy